Hospital-Acquired & Ventilator-Associated Pneumonia
Empiric HAP/VAP therapy built around local antibiogram risk, early respiratory sampling and rapid removal of unnecessary MRSA/dual gram-negative coverage.
Immediate priorities
- Obtain a high-quality respiratory specimen before changing antibiotics when feasible without delay
- Choose empiric therapy from the local ICU antibiogram and individual prior cultures
- Assess MDR and mortality risk rather than using identical triple therapy for every VAP
Diagnostics before and during therapy
- Respiratory culture (endotracheal aspirate or bronchoscopy-directed sample according to clinical context)
- Blood cultures in severe disease
- Chest imaging interpreted with trajectory and alternative diagnoses
- Review prior respiratory cultures/colonization
Empiric antimicrobial strategy
These are concrete empiric starting examples for the syndrome. Choose the option that fits acquisition setting, prior cultures and the local ICU antibiogram. Exact loading doses, renal/CRRT adjustments and infusion details stay in the medication monographs/local protocol.
Use when: Most HAP/VAP patients without a need for dual antipseudomonal therapy; select from the unit antibiogram and prior respiratory cultures.
- Add vancomycin or linezolid when MRSA coverage is indicated.
Use when: Selected VAP/HAP with major MDR risk, septic shock/high mortality risk, or an ICU where susceptibility to a proposed monotherapy agent is inadequate/unknown.
- De-escalate to one active agent as soon as susceptibility data allow.
Use an antipseudomonal beta-lactam active against local gram-negative pathogens
Add MRSA coverage when local prevalence/risk factors justify it
Use two antipseudomonal classes only for selected high-resistance/high-mortality risk scenarios, then de-escalate rapidly
Avoid aminoglycoside monotherapy for pneumonia and account for pulmonary penetration when choosing definitive therapy
Risk modifiers
Source control
- Drain empyema
- Address mucus plugging/airway obstruction
- Review ventilator circuit/aspiration prevention and remove unnecessary devices
Reassessment
- At 48–72 hours, decide whether pneumonia remains the best diagnosis
- De-escalate based on culture and clinical response
- Do not treat persistent radiographic opacity alone as ongoing infection
De-escalation
- Stop MRSA agent when MRSA is not supported
- Stop the second gram-negative agent once susceptibilities are known
- Prefer the narrowest active definitive agent with adequate lung exposure
Duration principles
- A 7-day course is appropriate for many uncomplicated HAP/VAP episodes with adequate clinical response
- Individualize for slow response, abscess/empyema, immunocompromise or unusual organisms